1 Nov 2013 07:00
Press Release | 1 November 2013 |
Avacta Group plc
("Avacta" or the "Group")
Issue of Equity
Avacta Group plc (AIM:AVCT), a global provider of innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, today announces that 929,411 Ordinary Shares of 0.1p ("new Ordinary Shares") have been issued by the Company pursuant to the exercise of share options by a former employee.
Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 6 November 2013.
The total number of Ordinary Shares in issue following the above issue will be 4,019,022,545 each with voting rights. No Ordinary Shares are held in Treasury.
The above figure of 4,019,022,545 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.
- Ends -
Enquiries:
Avacta Group plcAlastair Smith, Chief Executive OfficerTim Sykes, Chief Financial Officer | Tel: +44 (0) 844 414 0452 www.avacta.com |
Numis Securities LimitedMichael Meade / Freddie Barnfield - Nominated AdviserJames Black - Corporate Broking | Tel: +44 (0) 207 260 1000www.numiscorp.com |
Walbrook PR Ltd Paul McManus Lianne Cawthorne | Tel: +44 (0) 20 7933 8780 or avacta@walbrookpr.com Mob: +44 (0)7890 541 893 Mob: +44 (0)7584 391 303 |
Notes to Editors:
Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics.
Avacta's products address one of the most significant global challenges facing mankind today - the rapidly rising cost of healthcare for a growing and ageing population.
The cost of healthcare is driven by many factors. New drugs are expensive to develop, most don't reach the patient and those that do are often very costly to prescribe. Inadequate, incorrect or slow diagnosis causes delays that lead to longer or less effective courses of treatment resulting in lengthy or repeated hospitalisation.
Avacta is dedicated to developing and providing innovative and practical tools to help drug developers get their products to market quicker and more reliably, and to providing clinicians with rapid and powerful diagnostics to improve patient treatment, helping to reduce the cost of healthcare worldwide.
Avacta joined AIM in August 2006 and is based in Wetherby, England.
For further information visit www.avacta.com
Avacta Group (AVCT)